All In Biotech

Drug Trial Radar · NCT04774718

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Sep 14, 2021

Primary completion

Feb 28, 2032

Study completion Feb 28, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.

Conditions

  • ALK Fusion-positive Solid or CNS Tumors

Interventions

  • AlectinibDrug

    Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Participants with Dose-Limited Toxicities (DLTs)Time frame: Cycle 1 (cycle length = 28 days)
  2. Percentage of Participants with Adverse EventsTime frame: Up to 10 years
  3. Plasma Concentration of AlectinibTime frame: Up to 10 years
  4. Plasma Concentration of Alectinib Metabolite (M4)Time frame: Up to 10 years
  5. Confirmed Objective Response Rate (ORR): Defined as the Proportion of Participants with Complete Response (CR) or Partial Response (PR) on two Consecutive Occasions >/= 4 Weeks Apart, as Determined by Blinded Independent Central Review (BICR)Time frame: Up to 10 years

Locations

30 sites in 11 countries. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital

    Palo Alto, California

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida

  • University of Michigan, C.S. Mott Children's Hospital

    Ann Arbor, Michigan

  • Children's Minnesota

    Minneapolis, Minnesota

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • St. Jude Children'S Research Hospital

    Memphis, Tennessee

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia

  • Royal Children's Hospital

    Parkville, Victoria, Australia

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Graacc-Grupo de Apoio ao adolescente e a crianca com cancer

    São Paulo, São Paulo, Brazil

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Rigshospitalet

    København Ø, Denmark

  • Centre Léon Bérard, Institut d?Hémato-Oncologie Pédiatrique

    Lyon, France

  • Hôpital de la Timone, Oncologie Pédiatrique

    Marseille, France

  • Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris

    Paris, France

  • Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS

    Genoa, Liguria, Italy

  • Istituto Nazionale Tumori di Milano

    Milan, Lombardy, Italy

  • Dipartimento di Scienze Pediatriche Adolescenza

    Turin, Piedmont, Italy

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Hospital Infantil Universitario Nino Jesus

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Great Ormond Street Hospital

    London, United Kingdom

  • Royal Manchester Childrens Hospital

    Manchester, United Kingdom

  • Great North Children's Hospital

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.